tradingkey.logo
tradingkey.logo
Search

Nexalin Technology Inc

NXL
Add to Watchlist
0.361USD
-0.019-5.00%
Close 07/02, 13:00ETQuotes delayed by 15 min
7.43MMarket Cap
LossP/E TTM

More Details of Nexalin Technology Inc Company

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc Info

Ticker SymbolNXL
Company nameNexalin Technology Inc
IPO dateSep 16, 2022
CEOWhite (Mark)
Number of employees6
Security typeOrdinary Share
Fiscal year-endSep 16
Address1776 Yorktown
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77056
Phone18322600222
Websitehttps://nexalin.com
Ticker SymbolNXL
IPO dateSep 16, 2022
CEOWhite (Mark)

Company Executives of Nexalin Technology Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--

FAQs

Who are the top five shareholders of Nexalin Technology Inc?

The top five shareholders of Nexalin Technology Inc are: Ms. Marilyn Elson

How many institutions hold shares of Nexalin Technology Inc (NXL)?

As of 2026Q1, 43 institutions hold shares of Nexalin Technology Inc, with a combined market value of approximately 1.43M, accounting for 6.94% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 524945.00.

What is the biggest source of revenue for Nexalin Technology Inc?

In 2026Q1, the Device Sales business generated the highest revenue for Nexalin Technology Inc, amounting to 136.00K and accounting for 45.09% of total revenue.